Scientists at the University of Birmingham have developed a type of eye drop which could potentially revolutionise the treatment of one of the leading causes of blindness in the UK.
The results of the collaborative research, published today in Investigative Opthamology and Visual Science, could spell the end of painful injections directly into the eye to treat the increasingly common eye disorder known as age-related macular degeneration (AMD).
AMD affects more than 600,000 people in the UK and predictions suggest this figure could rise sharply in future because of an ageing population.
A painless condition which causes people to gradually lose their central vision, usually in both eyes, AMD is currently treated by repeated injections into the eye on a monthly basis over at least three years.
This is a problem because, apart from being an unpleasant procedure for patients to undergo, the injections can cause tearing and infections inside the eye and an increased risk of blindness.
Now scientists led by biochemist Dr Felicity de Cogan, from the University of Birmingham’s Institute of Inflammation and Ageing, have invented a method of delivering the injected drug as an eye drop instead, and their laboratory research has obtained the same outcomes as the injected drug.
The drop uses a cell-penetrating peptide (CPP) to deliver the drug to the relevant part of the eye within minutes.
Dr de Cogan said: “The CPP-drug has the potential to have a significant impact on the treatment of AMD by revolutionising drug-delivery options.
“Efficacious self-administered drug application by eye drop would lead to a significant reduction in adverse outcomes and health care costs compared with current treatments.
“The CPP-plus drug complex also has potential application to other chronic ocular diseases that require drug delivery to the posterior chamber of the eye.
“We believe this is going to be very important in terms of empowering of patients and reducing the cost of treatment to the NHS.”
The Latest on: Age-related macular degeneration
- Lutein Market Worth 357.7 Million USD by 2022 on December 13, 2017 at 2:05 am
Lutein plays a vital role in preventing age-related macular degeneration (AMD) disease. The Lutein Market, over the past few years, has been largely driven by the growing demand health supplements that contain lutein. Eye health supplements that contain ... […]
- Regeneron's sBLA for Eylea Accepted by FDA, Action Date Set on December 12, 2017 at 3:28 pm
The company is seeking approval a for a 12-week dosing interval of Eylea (aflibercept) Injection in patients with wet age-related macular degeneration (wet AMD) based on physician's assessment. The action date set by the FDA is Aug 11, 2018. So far this ... […]
- Juvenile Macular Degeneration Market by Major Solid Segments, Comprehensive Analysis, Success Milestones Forecasts by 2023 on December 12, 2017 at 10:05 am
As per the World Health Organization (WHO), nearly 11 million people in the U.S. have some form of age-related macular degeneration and the number is expected to reach nearly 22 million by 2050. Europe holds the second largest Juvenile Macular Degeneration ... […]
- A drug to treat retinal diseases with drops instead of injections on December 12, 2017 at 8:11 am
The Spanish firm Sylentis has developed a compound to treat diseases of the retina, such as age-related macular degeneration and diabetic retinopathy, which will be administered by ophthalmic drops instead of intraocular injections. The drug, which has ... […]
- ASK THE EXPERT: What is Macular Degeneration? on December 11, 2017 at 11:23 am
There is WET and DRY Age Related Macular Degeneration (AMD). Right now, there is no way to treat the dry form of AMD. However people with lots of drusen or serious vision loss might benefit from taking a certain combination of nutritional supplements.To ... […]
via Google News and Bing News